Meyer D M, Jessen M E
Department of Surgery (Division of Thoracic and Cardiovascular Surgery), University of Texas Southwestern Medical Center, Dallas 75235-8879.
J Thorac Cardiovasc Surg. 1995 Mar;109(3):419-425; discussion 425-7. doi: 10.1016/S0022-5223(95)70272-5.
Use of extracorporeal membrane oxygenation for treatment of respiratory failure caused by sepsis is controversial because of concerns over survival benefit and hemorrhage-related complications. To evaluate the impact of the primary diagnosis of sepsis on outcome, we reviewed data from 6853 neonates in the Extracorporeal Life Support Organization Registry and defined two groups: group 1 (n = 1060), all patients undergoing extracorporeal membrane oxygenation with a primary diagnosis of sepsis; group 2 (n = 5793), those with any other primary diagnosis. A multivariate logistic regression analysis that considered 15 variables present before extracorporeal membrane oxygenation (including age, sex, birth weight, prior cardiopulmonary arrest, arterial blood gas results, and ventilator settings) was used to compare outcomes between groups. Survival was not different between the two groups (77%, group 1; 82%, group 2; p = 0.2480), although lung recovery was less frequent in the patients with sepsis (p = 0.0185). Group 1 had a higher incidence of complications including seizures (odds ratio 1.446, p = 0.0346), cerebral infarct or hemorrhage (2.310, p = 0.0001), need for dialysis (1.478, p = 0.0131), hypernatremia (2.089, p = 0.0019), hyperbilirubinemia (2.423, p = 0.0001), and dobutamine use (1.918, p = 0.0001). Neonates with sepsis are more likely to have neurologic, renal, and metabolic complications from extracorporeal membrane oxygenation but may still achieve a survival benefit equivalent to those without sepsis. From these data, extracorporeal membrane oxygenation should not be withheld from neonates solely on the basis of sepsis. Rather, management strategies should focus on limiting the incidence or severity of the common complications.
由于对生存获益和出血相关并发症的担忧,体外膜肺氧合用于治疗脓毒症所致呼吸衰竭存在争议。为评估脓毒症的初始诊断对预后的影响,我们回顾了体外生命支持组织登记处6853例新生儿的数据,并将其分为两组:第1组(n = 1060),所有初始诊断为脓毒症且接受体外膜肺氧合的患者;第2组(n = 5793),具有任何其他初始诊断的患者。采用多因素逻辑回归分析,该分析考虑了体外膜肺氧合前存在的15个变量(包括年龄、性别、出生体重、既往心肺骤停、动脉血气结果和呼吸机设置),以比较两组的预后。两组的生存率无差异(第1组为77%;第2组为82%;p = 0.2480),尽管脓毒症患者的肺恢复情况较少见(p = 0.0185)。第1组的并发症发生率较高,包括癫痫发作(比值比1.446,p = 0.0346)、脑梗死或出血(2.310,p = 0.0001)、需要透析(1.478,p = 0.0131)、高钠血症(2.089,p = 0.0019)、高胆红素血症(2.423,p = 0.0001)以及使用多巴酚丁胺(1.918,p = 0.0001)。脓毒症新生儿接受体外膜肺氧合时更易出现神经、肾脏和代谢并发症,但仍可能获得与非脓毒症新生儿相当的生存获益。基于这些数据,不应仅因脓毒症而不给新生儿使用体外膜肺氧合。相反,管理策略应侧重于限制常见并发症的发生率或严重程度。